Renal injury in streptozotocin-diabetic Ren2-transgenic rats is mainly dependent on hypertension, not on diabetes

American Journal of Physiology - Renal Physiology

Volumn 292, Issue 2, 2007, Pages

  Hartner, Andrea ^a   Cordasic, Nada ^a   Klanke, Bernd ^a   Wittmann, Michael ^b   Veelken, Roland ^a   Hilgers, Karl F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b KLINIKUM AUGSBURG   (Germany)

Author keywords

Angiotensin; Glomerulosclerosis; Macrophages; Nephrosclerosis

Indexed keywords

ALBUMIN; ANGIOTENSIN; COLLAGEN TYPE 4; LOSARTAN;

ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GENE; GLUCOSE BLOOD LEVEL; HYPERTENSION; LOW DRUG DOSE; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REN GENE; STREPTOZOCIN DIABETES; SURVIVAL; TRANSGENIC ANIMAL;

EID: 33846881162     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00088.2006     Document Type: Article

References (39)

1. Anderson S, Brenner BM. Pathogenesis of diabetic glomerulopathy: hemodynamic considerations. Diabetes Metab Rev 4: 163-177, 1988.
2. Bader M, Zhao Y, Sander M, Lee MA, Bachmann J, Bohm M, Djavidani B, Peters J, Mullins JJ, Ganten D. Role of tissue renin in the pathophysiology of hypertension in TGR(mREN2)27 rats. Hypertension 19: 681-686, 1992.
3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
4. Breyer MD, Bottinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, Sharma K. Mouse models of diabetic nephropathy. J Am Soc Nephrol 16: 27-45, 2005.
5. Campbell DJ, Kelly DJ, Wilkinson-Berka JL, Cooper ME, Skinner SL. Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. Kidney Int 56: 211-221, 1999.
6. Djavidani B, Sander M, Kreutz R, Zeh K, Bader M, Mellon SH, Vecsei P, Peters J, Ganten D. Chronic dexamethasone treatment suppresses hypertension development in the transgenic rat TGR(mREN2)27. J Hypertens 13: 637-645, 1995.
7. Hartner A, Hilgers KF, Wittmann M, Ganten D, Sterzel RB, Veelken R. Glomerular monocyte chemoattractant protein-1 expression and macrophages in insulin-dependent diabetes mellitus and hypertension (Abstract). J Am Soc Nephrol 9: 632A, 1998.
8. Hartner A, Porst M, Klanke B, Cordasic N, Veelken R, Hilgers KF. Angiotensin II formation in the kidney and nephrosclerosis in Ren-2 hypertensive rats. Nephrol Dial Transplant 21: 1778-1785, 2006.
9. Hartner A, Veelken R, Wittmann M, Cordasic N, Hilgers KF. Effects of diabetes and hypertension on macrophage infiltration and matrix expansion in the rat kidney. BMC Nephrol 6: 6, 2005.
10. Hilgers KF, Hartner A, Porst M, Veelken R, Mann JF. Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation. Circulation 104: 1436-1440, 2001.
11. Hilgers KF, Peters J, Veelken R, Sommer M, Rupprecht G, Ganten D, Luft FC, Mann JF. Increased vascular angiotensin formation in female rats harboring the mouse Ren-2 gene. Hypertension 19: 687-691, 1992.
12. Hollenberg NK, Price DA, Fisher ND, Lansang MC, Perkins B, Gordon MS, Williams GH, Laffel LM. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 63: 172-178, 2003.
13. Hui AY, Leung WK, Chan HL, Chan FK, Go MY, Chan KK, Tang BD, Chu ES, Sung JJ. Effect of celecoxib on experimental liver fibrosis in rat. Liver Int 26: 125-136, 2006.
14. Janssen U, Phillips AO, Floege J. Rodent models of nephropathy associated with type II diabetes. J Nephrol 12: 159-172, 1999.
15. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int 54: 343-352, 1998.
16. Kelly DJ, Wilkinson-Berka JL, Ricardo SD, Cox AJ, Gilbert RE. Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2)27 rats. Nephrol Dial Transplant 17: 985-991, 2002.
17. Komers R, Anderson S. Treatment of hypertension in diabetic patients with nephropathy. Curr Diab Rep 1: 251-260, 2001.
18. Konishi A, Tazawa C, Miki Y, Darnel AD, Suzuki T, Ohta Y, Suzuki T, Tabayashi K, Sasano H. The possible roles of mineralocorticoid receptor and 11-hydroxysteroid dehydrogenase type 2 in cardiac fibrosis in the spontaneously hypertensive rat. J Steroid Biochem Mol Biol 85: 439-442, 2003.
19. Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE. Recommendations for blood pressure measurement in humans and experimental animals. Part 2. Blood pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. Hypertension 45: 299-310, 2005.
20. Langheinrich M, Lee MA, Bohm M, Pinto YM, Ganten D, Paul M. The hypertensive Ren-2 transgenic rat TGR (mREN2)27 in hypertension research. Characteristics and functional aspects. Am J Hypertens 9: 506-512, 1996.
21. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
22. Linden KC, DeHaan CL, Zhang Y, Glowacka S, Cox AJ, Kelly DJ, Rogers S. Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. Am J Physiol Renal Physiol 290: F205-F213, 2006.
23. Mai M, Hilgers KF, Wagner J, Mann JF, Geiger H. Expression of angiotensin-converting enzyme in renovascular hypertensive rat kidney. Hypertension 25: 674-678, 1995.
24. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14: 1358-1373, 2003.
25. Michels LD, Davidman M, Keane WF. Determinants of glomerular filtration and plasma flow in experimental diabetic rats. J Lab Clin Med 98: 869-885, 1981.
26. Mifsud SA, Skinner SL, Cooper ME, Kelly DJ, Wilkinson-Berka JL. Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats. J Am Soc Nephrol 13: 684-692, 2002.
27. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344: 541-544, 1990.
28. O'Donnell MP, Kasiske BL, Keane WF. Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. FASEB J 2: 2339-2347, 1988.
29. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001.
30. Peters J, Munter K, Bader M, Hackenthal E, Mullins JJ, Ganten D. Increased adrenal renin in transgenic hypertensive rats, TGR(mREN2)27, and its regulation by cAMP, angiotensin II, and calcium. J Clin Invest 91: 742-747, 1993.
31. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341: 1127-1133, 1999.
32. Ruiz V, Ordonez RM, Berumen J, Ramirez R, Uhal B, Becerril C, Pardo A, Selman M. Unbalanced collagenases/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol 285: L1026-L1036, 2003.
33. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703-713, 1998.
34. Veelken R, Hilgers KF, Ditting T, Leonard M, Mann JF, Geiger H, Luft FC. Impaired cardiovascular reflexes precede deoxycorticosterone acetate-salt hypertension. Hypertension 24: 564-570, 1994.
35. Veelken R, Hilgers KF, Porst M, Krause H, Hartner A, Schmieder RE. Effects of sympathetic nerves and angiotensin II on renal sodium and water handling in rats with common bile duct ligature. Am J Physiol Renal Physiol 288: F1267-F1275, 2005.
36. Whitworth CE, Fleming S, Cumming AD, Morton JJ, Burns NJ, Williams BC, Mullins JJ. Spontaneous development of malignant phase hypertension in transgenic Ren-2 rats. Kidney Int 46: 1528-1532, 1994.
37. Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, Cooper ME. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 51: 3283-3289, 2002.
38. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 34: 785-796, 2004.
39. Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 29: 153-163, 1997.